Back Translation for Patient-Reported Outcomes: Why Questionnaire Validation Requires It

Key Takeaways

• Patient-reported outcome (PRO) instruments used in clinical trials and regulatory submissions must undergo linguistic validation before use in each target language. Back translation is a mandatory step in that process.
• PRO linguistic validation follows a defined multi-step methodology: forward translation, back translation, expert committee review, cognitive debriefing with patients, and final reconciliation. Back translation sits at stage two and cannot be skipped.
• The purpose of back translation in PRO validation is to verify conceptual equivalence, not linguistic identity. A PRO item that means something different in translation than in the original will produce data that cannot be compared across language versions of the same trial.
• Regulatory authorities including EMA and FDA have published guidance on PRO instrument development and linguistic validation. Sponsors submitting PRO data as a primary or secondary endpoint must demonstrate that validated translations were used.
• Cognitive debriefing with native-speaking patients is a required step after back translation in PRO validation. Back translation alone does not confirm that a translated item is understood by patients in the way the instrument developer intended.

Patient-reported outcome instruments are questionnaires completed directly by patients to capture how they feel, how they function, and how their condition affects their daily life. In clinical trials they are used to measure treatment benefit from the patient's perspective, and in many therapeutic areas they form primary or key secondary endpoints that regulatory authorities use to evaluate whether a new therapy should be approved.

When a PRO instrument is used across multiple countries in a multinational trial, every language version must be a validated translation of the original. Not just an accurate translation, but one that has been shown through a structured validation process to capture the same concepts, carry the same meaning, and be understood by patients in the same way as the original instrument.

Back translation is a central step in that process.

What PRO linguistic validation involves

PRO linguistic validation follows a methodology developed by the measurement science and regulatory communities over several decades. The standard process involves the following stages.

Forward translation. Two independent translators, both native speakers of the target language with relevant clinical or scientific background, produce independent forward translations of the original instrument. These are reconciled into a single draft by a project coordinator.

Back translation. The reconciled forward translation is back-translated into the source language by one or more independent translators who are native speakers of the source language and have not seen the original instrument. The back translation is compared with the original to identify any items where the forward translation may have shifted meaning.

Expert committee review. A committee including the translators, a methodologist, and a clinical or subject matter expert reviews the forward translation, back translation, and discrepancy analysis. The committee resolves any identified issues and produces a pre-final version of the instrument.

Cognitive debriefing. The pre-final translated instrument is tested with a small sample of native-speaking patients from the target population. Patients complete the questionnaire and are asked to explain in their own words what each item means to them. This step identifies items that are accurately translated but not understood as intended.

Final reconciliation and documentation. Findings from cognitive debriefing are used to finalise the instrument. The full validation process is documented in a linguistic validation report.

Why back translation matters in PRO validation

PRO instruments measure subjective patient experience. The meaning of individual items is precise by design, because the instrument has been developed and validated to measure a specific construct with defined boundaries. A question that asks about "difficulty climbing stairs" and a question that asks about "pain when climbing stairs" measure different things, even though both concern stairs.

When a forward translation produces an item that is linguistically natural in the target language but subtly shifts the construct being measured, that shift may be invisible to a bilingual reviewer reading both versions. It becomes visible in the back translation, where the altered meaning is rendered back into the source language in a way that departs from the original item.

This is why back translation in PRO validation is not simply a general quality check. It is specifically designed to surface construct-level divergence that bilingual review does not reliably detect.

What regulators expect

The EMA's Reflection Paper on the regulatory guidance for the use of health-related quality of life measures and the FDA's guidance on PRO measures in medical product development both emphasise the importance of validated translations. Sponsors submitting PRO data as a primary endpoint, or using a PRO instrument to support a label claim, must be able to demonstrate that the translation used was validated according to accepted methodology.

Where sponsors use non-validated translations, regulatory reviewers may question whether the PRO data collected in different language versions of the trial is genuinely comparable. In some cases this has led to requests for additional evidence or qualification of the PRO data in the product label.

What a PRO back translation package contains

A back translation produced as part of PRO linguistic validation should include:

• The reconciled forward translation used as the source for back translation
• The back translation itself, with confirmation that the back translator had no access to the original instrument
• A structured item-by-item comparison of the original and back-translated versions
• A discrepancy analysis noting any items where the back translation diverges substantively from the original
• The expert committee's assessment of each discrepancy and the resolution applied
• Updated forward translation where items were revised following back translation review

This package is retained as part of the linguistic validation documentation and may be requested by regulatory authorities during the review of a marketing authorisation application.

Working with a specialist PRO translation partner

PRO linguistic validation requires translators with both linguistic credentials and an understanding of the measurement science principles behind PRO instrument development. A general translator who produces a fluent and accurate translation of a quality of life questionnaire may still produce a version that fails cognitive debriefing because an item, though correctly translated, is understood differently by patients than the original intended.

Global LTS provides back translation and full linguistic validation support for PRO instruments across 120+ languages. Our clinical translation team works within the established PRO validation methodology and produces documentation formatted for regulatory submission.

To discuss your PRO linguistic validation requirements, visit our back translation services page or our medical translation services page.